Description
Brentuximab vedotin associated with durable remissions and long-term survival in patients with relapsed/ refractory Hodgkins’ lymphoma
Article: Brentuximab vedotin associated with durable remissions and long-term survival in patients with relapsed/ refractory Hodgkins’ lymphoma
€3.03
Related products
-
Article: Highlights in respiratory oncology
€3.03 Add to cart -
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart -
Article: Highlights in squamous cell carcinoma of the head and neck
€3.03 Add to cart -
Article: Highlights in genitourinary cancers
€3.03 Add to cart
